AXL and acute myeloid leukemia: Since AML cells with FLT3-ITD mutation co-express not only Wt-FLT3, but also other Wt-RTKs such as KIT and AXL [30, 31], inhibitory effects of FLT3 inhibitors might be impaired by their ligands.